Indications
Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control. in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.
Composition
- Active substance
- ertugliflozin l-pyroglutamic acid, sitagliptin phosphate monohydrate
- International name (INN)
- ertugliflozin;sitagliptin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Steglujan
- Active substance
- ertugliflozin l-pyroglutamic acid, sitagliptin phosphate monohydrate
- ATC code
- A10BD24